Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Prurigo Nodularis (OLYMPIA 2)
NCT04501679Phase 3Completed
- Sponsor
- Galderma
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of nemolizumab in prurigo nodularis (PN), sponsored by Galderma. Started Aug 2020; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT04501679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501679.